Log in

Heska (NASDAQ:HSKA) Stock Rating Lowered by ValuEngine

Last updated on Thursday, July 2nd, 2020 by MarketBeat

Heska (NASDAQ:HSKA) was downgraded by equities research analysts at ValuEngine from a "buy" rating to a "hold" rating in a report released on Thursday, ValuEngine reports.

Other research analysts have also issued research reports about the company. TheStreet lowered Heska from a "c-" rating to a "d+" rating in a report on Friday, April 3rd. Sidoti dropped their price target on Heska from $77.00 to $59.00 and set a "neutral" rating for the company in a research report on Friday, March 27th. Alliance Global Partners lifted their price target on Heska from $78.00 to $90.00 in a research report on Friday, May 8th. BidaskClub upgraded Heska from a "hold" rating to a "buy" rating in a research report on Tuesday, May 12th. Finally, Zacks Investment Research downgraded Heska from a "buy" rating to a "hold" rating in a research report on Tuesday. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of "Hold" and a consensus target price of $81.67.

HSKA stock opened at $92.83 on Thursday. The company has a quick ratio of 9.89, a current ratio of 11.21 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $856.17 million, a PE ratio of -92.83 and a beta of 1.73. Heska has a twelve month low of $50.00 and a twelve month high of $110.90. The stock has a 50-day simple moving average of $85.72 and a two-hundred day simple moving average of $85.32.

Heska (NASDAQ:HSKA) last posted its earnings results on Thursday, May 7th. The medical research company reported ($0.70) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by ($0.44). The company had revenue of $30.65 million for the quarter, compared to analysts' expectations of $33.47 million. Heska had a negative net margin of 5.99% and a negative return on equity of 1.04%. On average, equities research analysts anticipate that Heska will post -0.81 EPS for the current fiscal year.

In related news, CEO Kevin S. Wilson sold 3,266 shares of the business's stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $85.00, for a total value of $277,610.00. Following the completion of the sale, the chief executive officer now owns 104,955 shares in the company, valued at approximately $8,921,175. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin S. Wilson sold 10,000 shares of the business's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $91.00, for a total value of $910,000.00. Following the completion of the sale, the chief executive officer now owns 82,955 shares of the company's stock, valued at approximately $7,548,905. The disclosure for this sale can be found here. Insiders sold a total of 30,941 shares of company stock valued at $2,741,842 in the last 90 days. 11.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in HSKA. FMR LLC lifted its position in Heska by 2.0% in the 1st quarter. FMR LLC now owns 453,664 shares of the medical research company's stock worth $38,616,000 after buying an additional 8,870 shares during the last quarter. Swiss National Bank increased its stake in Heska by 1.4% in the 4th quarter. Swiss National Bank now owns 14,100 shares of the medical research company's stock worth $1,353,000 after purchasing an additional 200 shares during the period. Victory Capital Management Inc. increased its stake in Heska by 39.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,445 shares of the medical research company's stock worth $139,000 after purchasing an additional 412 shares during the period. PNC Financial Services Group Inc. increased its stake in Heska by 67.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,241 shares of the medical research company's stock worth $312,000 after purchasing an additional 1,303 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Heska by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,474 shares of the medical research company's stock worth $4,171,000 after purchasing an additional 2,030 shares during the period. Institutional investors own 79.78% of the company's stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

See Also: How to Trade Using Analysts Ratings

To view ValuEngine's full report, visit ValuEngine's official website.

Analyst Recommendations for Heska (NASDAQ:HSKA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Stocks You Can Count On During Any Crisis

Depending on how you look at it, the economic outlook is getting cloudier or clearer.

The argument for a cloudy economy is easy to make. Multiple times of day we hear about more Americans testing positive for the novel coronavirus. The worldwide number of positive tests exceeds one million. And unfortunately, it will go higher. We just don’t know by how much.

But there are two parts to this ongoing situation. The first is the real-time science experiment as the world attempts to flatten the curve. The other is the very real economic impact. And the numbers of the economic carnage are coming in faster than any significant evidence of a flattening curve.

The number of unemployed now exceeds six million and will only rise. The government is throwing everything including the kitchen sink at the problem. But it’s an experiment in real-time. We won’t know the results for some time.

But even while we wait for a new normal to return, there are ways for you to profit. There are companies that are keeping our economy going now, and have a business model that sets them up well for success after the pandemic is over.

View the "8 Stocks You Can Count On During Any Crisis".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.